Combination of PI3K inhibitors and mTOR inhibitors, dual mTORC1/2 inhibition, and mTOR and receptor tyrosine kinase inhibitors are strategies being explored for cancers of endocrine tissues in which the PI3K/Akt/mTOR pathway is hyperactivated (21). This evidence concerns the gene NTRK1 and cancer.